Kelyniam Global, Inc. renews licensing agreement with Finceramica Faenza S.p.A., granting access to advanced biomaterials like SINTlife. This partnership aims to expand beyond cranial implants into regenerative medicine, with SINTlife expected to receive FDA clearance within 2 years, targeting larger markets. The agreement highlights the strategic alignment between the two companies, positioning Kelyniam for growth in multimillion-dollar markets. Kelyniam specializes in custom prosthetics, while Finceramica focuses on regenerative surgery solutions. The collaboration aims to bring innovative biomaterials to patients in need, creating opportunities for collaborative success in high-impact markets.

Read more at GlobeNewswire: Kelyniam Global Renews Licensing Agreement with